What’s Going On With Amgen Stock On Friday?
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, […]
Read More